Open label safety evaluation of specific immunotherapy in subjects aged 5-17 years suffering from seasonal rhinoconjunctivitis due to grass pollen not responding to pharmacotherapy

Trial Profile

Open label safety evaluation of specific immunotherapy in subjects aged 5-17 years suffering from seasonal rhinoconjunctivitis due to grass pollen not responding to pharmacotherapy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 May 2006

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Adverse reactions
  • Most Recent Events

    • 05 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top